3 results match your criteria: "Hospital e Maternidade Celso Pierro-PUC[Affiliation]"

Importance: Immune dysregulation contributes to poorer outcomes in COVID-19.

Objective: To investigate whether abatacept, cenicriviroc, or infliximab provides benefit when added to standard care for COVID-19 pneumonia.

Design, Setting, And Participants: Randomized, double-masked, placebo-controlled clinical trial using a master protocol to investigate immunomodulators added to standard care for treatment of participants hospitalized with COVID-19 pneumonia.

View Article and Find Full Text PDF

[Adjuvant drug treatment in diabetic patients undergoing percutaneous coronary intervention].

Arq Bras Endocrinol Metabol

March 2007

Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, USP, São Paulo, and Laboratório de Hemodinâmica e Cardiologia Intervencionista, Hospital e Maternidade Celso Pierro-PUC, Campinas, SP, Brazil.

Article Synopsis
  • The study discusses the use of adjuvant drug treatments during and after percutaneous coronary intervention (PCI) to reduce major cardiovascular events in diabetic patients.
  • Special emphasis is placed on managing cardiovascular risk factors, with maintaining normal blood sugar levels being crucial for patient care.
  • The authors highlight the debate around antiplatelet therapy, recommending that the use of GPIIb/IIIa agents should only be reserved for diabetic patients with significant thrombotic risk rather than being universally applied.
View Article and Find Full Text PDF

Background: Febrile neutropenia is a frequent event for cancer patients undergoing chemotherapy and it is potentially a life threatening situation. The current treatment is supportive care plus antibiotics. Colony stimulating factors (CSF) are cytokines that stimulate and accelerate the production of one or more cellular lines in bone marrow.

View Article and Find Full Text PDF